Table 1.
Relations between the presence of hybrid E/M cancer cells and clinicopathological variables.
| Variable | Category | E/M score > 2% | p-Value 1 | |
|---|---|---|---|---|
| T | Ta–T1 (n = 48) | 6 | (13%) | <10−6 |
| T2–T4 (n = 65) | 38 | (58%) | ||
| N | N0 (n = 92) | 32 | (35%) | 0.08 |
| N+ (n = 31) | 12 | (57%) | ||
| M | M0 (n = 108) | 41 | (38%) | 0.38 |
| M1 (n = 5) | 3 | (60%) | ||
| Stage | 0–I (n = 48) | 6 | (13%) | <10−6 |
| II–IV (n = 65) | 38 | (58%) | ||
| Grade | low (n = 25) | 1 | (4%) | 0.00002 |
| high (n = 88) | 43 | (49%) | ||
| Divergent differentiation | no (n = 88) | 29 | (33%) | 0.02 |
| yes (n = 25) | 15 | (60%) | ||
| CIS 2 | no (n = 83) | 27 | (33%) | 0.03 |
| yes (n = 30) | 17 | (57%) | ||
| Multifocality | no (n = 91) | 40 | (44%) | 0.03 |
| yes (n = 22) | 4 | (18%) | ||
| LVI 3 | no (n = 72) | 24 | (33%) | 0.11 |
| yes (n = 41) | 20 | (49%) | ||
1 Two-tailed Fisher’s exact test; 2 concomitant in situ carcinoma; 3 lymphovascular invasion.